Cover Image
市場調查報告書

兔熱病:開發中產品分析

Tularaemia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 293888
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
兔熱病:開發中產品分析 Tularaemia - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 72 Pages
簡介

兔熱病(tularaemia)是由一種被稱為土拉桿菌(Francisella tularensis)的細菌所引起的感染病。主要是因被節肢動物(特別是扁虱和蚊子)虰咬感染。藉由皮膚、結膜囊、口腔咽喉黏膜與感染的動物及動物性物質直接接獨、或攝取到被污染的食品及水、吸入被污染的灰塵粉霧而感染。主要症狀有皮膚潰瘍、淋巴腺腫大和疼痛、發燒、發冷等。治療方法包含了抗生素和健康生活習慣等。

本報告提供兔熱病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

兔熱病概要

治療藥的開發

  • 開發中產品:概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aradigm Corp
  • Arno Therapeutics Inc
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Grifols SA
  • Merck & Co Inc
  • Tetraphase Pharmaceuticals Inc

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9886IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Tularaemia - Overview 6
  • Tularaemia - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 9
  • Products under Development by Companies 10
  • Products under Development by Universities/Institutes 11
  • Tularaemia - Therapeutics Assessment 12
  • Assessment by Target 12
  • Assessment by Mechanism of Action 14
  • Assessment by Route of Administration 16
  • Assessment by Molecule Type 18
  • Tularaemia - Companies Involved in Therapeutics Development 20
  • Aradigm Corp 20
  • Arno Therapeutics Inc 20
  • DynPort Vaccine Company LLC 21
  • Emergent BioSolutions Inc 21
  • EpiVax Inc 22
  • Grifols SA 22
  • Merck & Co Inc 22
  • Tetraphase Pharmaceuticals Inc 23
  • Tularaemia - Drug Profiles 24
  • AR-12 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • ARD-3100 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • ARD-3150 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • ciprofloxacin hydrochloride - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • EV-035 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • infectious disease vaccines - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • NDBR-101 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Small Molecules for Infectious Diseases - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • solithromycin - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • SRI-011225 - Drug Profile 58
  • Product Description 58
  • Mechanism Of Action 58
  • R&D Progress 58
  • TP-271 - Drug Profile 59
  • Product Description 59
  • Mechanism Of Action 59
  • R&D Progress 59
  • tularaemia [strain A] vaccine - Drug Profile 62
  • Product Description 62
  • Mechanism Of Action 62
  • R&D Progress 62
  • tularaemia [strain B] vaccine - Drug Profile 63
  • Product Description 63
  • Mechanism Of Action 63
  • R&D Progress 63
  • tularaemia vaccine - Drug Profile 64
  • Product Description 64
  • Mechanism Of Action 64
  • R&D Progress 64
  • tularemia vaccine - Drug Profile 65
  • Product Description 65
  • Mechanism Of Action 65
  • R&D Progress 65
  • Tularaemia - Dormant Projects 66
  • Tularaemia - Discontinued Products 67
  • Tularaemia - Product Development Milestones 68
  • Featured News & Press Releases 68
  • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 68
  • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 69
  • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 69
  • Appendix 71
  • Methodology 71
  • Coverage 71
  • Secondary Research 71
  • Primary Research 71
  • Expert Panel Validation 71
  • Contact Us 71
  • Disclaimer 72

List of Tables

  • Number of Products under Development for Tularaemia, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Products under Development by Companies, H2 2017 10
  • Products under Development by Universities/Institutes, H2 2017 11
  • Number of Products by Stage and Target, H2 2017 13
  • Number of Products by Stage and Mechanism of Action, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 17
  • Number of Products by Stage and Molecule Type, H2 2017 19
  • Tularaemia - Pipeline by Aradigm Corp, H2 2017 20
  • Tularaemia - Pipeline by Arno Therapeutics Inc, H2 2017 20
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2017 21
  • Tularaemia - Pipeline by Emergent BioSolutions Inc, H2 2017 21
  • Tularaemia - Pipeline by EpiVax Inc, H2 2017 22
  • Tularaemia - Pipeline by Grifols SA, H2 2017 22
  • Tularaemia - Pipeline by Merck & Co Inc, H2 2017 23
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 23
  • Tularaemia - Dormant Projects, H2 2017 66
  • Tularaemia - Discontinued Products, H2 2017 67

List of Figures

  • Number of Products under Development for Tularaemia, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Number of Products by Top 10 Targets, H2 2017 12
  • Number of Products by Stage and Top 10 Targets, H2 2017 12
  • Number of Products by Top 10 Mechanism of Actions, H2 2017 14
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14
  • Number of Products by Routes of Administration, H2 2017 16
  • Number of Products by Stage and Routes of Administration, H2 2017 16
  • Number of Products by Molecule Types, H2 2017 18
  • Number of Products by Stage and Molecule Types, H2 2017 18
Back to Top